Spero therapeutics announces first quarter 2025 operating results and provides a business update

Cambridge, mass., may 13, 2025 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced financial results for the first quarter ended march 31, 2025, and provided a business update.
SPRO Ratings Summary
SPRO Quant Ranking